RelieVRx maintained clinically meaningful effects in reducing pain intensity and pain-related impairment of activity, stress and sleep six months after treatment
LOS ANGELES, July 21, 2022 /PRNewswire/ — Applied VRa pioneer of immersive therapeutics advancing a novel medical approach, today announced the results of a follow-up study analyzing the long-term effects of its flagship product, RelieVRx, recently conducted granted market approval by the FDA for chronic low back pain (CLBP).
The research was published in the Journal of Medical Internet Research (JMIR) and reported the six-month follow-up results of a previous rrandomized controlled trial (RCT) by RelieVRx (formerly called EaseVRx). Researchers sought to assess the sustained effects of the eight-week, self-administered, behavioral skills-based VR program RelieVRx compared to sham VR in 188 adults with CLBP.
The AppliedVR study, which included surveys of RCT participants, found that RelieVRx achieved superior benefits compared to the VR sham control group on many of the pain-related indices measured six months after treatment. Specifically, the study highlighted:
- The mean improvement in pain intensity six months after treatment was 31.3%;
- The mean improvement in pain-related activity impairment six months after treatment was 34.8%;
- The mean improvement in pain-related mood disorder six months after treatment was 39.2%;
- The mean improvement in pain-related sleep disorders six months after treatment was 44.5%; and
- The mean improvement in pain-related interference with stress was 42.5%.
All of these results cross the threshold to be considered “clinically meaningful” and provide important evidence supporting the effectiveness of at-home VR treatment for lasting pain relief. The researchers also found statistically significant improvements in study participants’ physical functioning and sleep disorders six months after treatment.
A 2020 to learn in the Journal of American Medical Association found that costs associated with lower back and neck injuries were exaggerated $134 billionmaking it the most costly category of healthcare spending in the country.
“Immersive VR therapeutics offer people living in pain a powerful, easy-to-use prescription treatment modality that gives them the skills they need to self-regulate their chronic pain, and this study further validates how RelieVRx can be safely used by people in the home to provide lasting pain relief achieve,” said Josh Sackman, Co-Founder and President of AppliedVR. “The healthcare industry should not expect that people with chronic pain will always need expensive surgeries or take pills for life in order to live happier lives. Therefore, all healthcare stakeholders are looking for science-based alternatives like VR. But we can’t expect people to spend their lives in VR headsets, so we’re very encouraged by these results. Our goal is to create an unprecedented body of evidence that shows VR can be an effective, accessible, scalable and durable solution for everyone.”
AppliedVR is currently building on its research with a new 1,000-participant RCT that will examine healthcare usage data via an included claims dataset Partnership with Komodo. In addition, the study will evaluate the effectiveness, durability, and accessibility of VR for a broader, more diverse group of individuals across race, gender, and socioeconomic status (SES).
AppliedVR creates a new reality in healthcare. We are pioneering immersive therapeutics (ITx), a new category of medicine to treat intractable health conditions like chronic pain, behavioral and mental health disorders that affect millions of people worldwide. Today, AppliedVR treatments represent a comprehensive approach to chronic pain, empowering patients with an intuitive device they can self-manage at home. AppliedVR’s RelieVRx is the first VR-based prescription therapeutic to receive FDA Breakthrough Therapy Designation and De Novo Clearance for chronic low back pain (CLBP). In addition to RelieVRx, AppliedVR’s pain management and wellness programs are trusted by more than 200 leading healthcare systems and thousands of healthcare professionals worldwide treating more than 60,000 patients. For more information visit www.appliedvr.io.
View the original content to download multimedia:https://www.prnewswire.com/news-releases/appliedvr-announces-results-from-a-clinical-trial-follow-up-study-finding-relievrx-delivers-durable-effects-six-months-after- Final treatment-301590671.html